+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 100Years
FEMALE
ID06052696

Randomized Placebo-Controlled Trial of Nonavalent HPV Vaccination to Prevent Recurrence in Women Treated for Vulvar HSIL

Led by Erasmus Medical Center · Updated on 2026-09-15

500

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of the nonavalent HPV vaccine in preventing recurrence of vulvar High Grade Squamous Intraepithelial Lesion vHSIL, a premalignant condition related to HPV that affects women, mainly between ages 35 and 40. Vulvar HSIL has a high recurrence rate after treatment, leading to repeated interventions and increased risk of vulvar cancer. This study aims to compare HPV vaccination with placebo to reduce recurrences and improve quality of life. Participants will be randomly assigned to receive either three doses of the Gardasil 9 vaccine or placebo injections, administered around their planned treatment for vHSIL, which may include surgery, laser, or topical imiquimod. The vaccination schedule involves a first injection near treatment start, a second injection at least one month later, and a third injection three months after the second, all within one year. During the study, women will be monitored for recurrence of vHSIL up to 24 months after inclusion, with evaluations at 6, 12, and 24 months, including quality of life and sexual health assessments. Additional long-term follow-up will assess recurrence and cancer development over 5 to 10 years. Researchers will also measure antibody levels, HPV types, treatment effectiveness, and cost-effectiveness. Safety and recurrence data will be closely observed throughout the study duration.

CONDITIONS

Brief Title

Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here